newsfilter
← Latest News
GlobeNewswire·

Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results

NDA for govorestat accepted and granted Priority Review by FDA for the treatment of Classic Galactosemia; PDUFA target action date of August 28, 2024; MAA under review by EMA with decision expected in 4Q 2024 Announced